Leerink Partners Issues Positive Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price

Myriad Genetics (NASDAQ:MYGN) had its price objective lifted by equities researchers at Leerink Partners from $5.00 to $8.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a “market perform” rating on the stock. Leerink Partners‘s price target would indicate a potential upside of 28.51% from the company’s previous close.

MYGN has been the topic of a number of other reports. UBS Group began coverage on shares of Myriad Genetics in a research report on Wednesday, September 9th. They set a “neutral” rating and a $3.60 target price on the stock. Wells Fargo & Company set a $4.50 price target on Myriad Genetics in a report on Tuesday, October 20th. Piper Sandler raised Myriad Genetics from an “underweight” rating to a “neutral” rating and set a $5.00 price objective on the stock in a research note on Tuesday, October 20th. Craig Hallum raised their price objective on Myriad Genetics from $4.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Finally, Zacks Research raised Myriad Genetics from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Myriad Genetics presently has an average rating of “Hold” and a consensus price target of $5.23.

Myriad Genetics Trading Up 3.4%

Shares of NASDAQ MYGN traded up $0.20 during mid-day trading on Thursday, reaching $6.22. The company had a trading volume of 2,211,760 shares, compared to its average volume of 1,895,261. The stock has a market cap of $595.42 million, a price-to-earnings ratio of -5.27 and a beta of 1.62. Myriad Genetics has a 52 week low of $2.74 and a 52 week high of $8.09. The business’s 50-day moving average is $4.38 and its 200-day moving average is $4.62. The company has a current ratio of 2.21, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.09. The company had revenue of $202.70 million during the quarter, compared to analyst estimates of $191.33 million. Myriad Genetics had a negative net margin of 13.96% and a negative return on equity of 16.09%. Equities analysts expect that Myriad Genetics will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Orbimed Advisors LLC acquired a new stake in Myriad Genetics during the first quarter worth about $562,500,000. BlackRock Inc. purchased a new position in Myriad Genetics during the second quarter valued at approximately $62,184,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Myriad Genetics in the second quarter valued at approximately $8,039,000. Man Group plc acquired a new position in Myriad Genetics in the second quarter valued at approximately $5,189,000. Finally, Bank of America Corp DE purchased a new stake in Myriad Genetics in the 2nd quarter worth approximately $5,150,000. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Key Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, up 6% sequentially, and a loss of $0.11 per share—narrower than analysts’ expected $0.20 loss. Revenue also exceeded estimates. Read More.
• Positive Sentiment: The company raised the midpoint of its 2026 revenue guidance, citing execution and improved revenue per test. It also agreed to sell its Prenatal Health business for $210 million, a transaction Myriad says will support strategic growth initiatives. Read More.
• Neutral Sentiment: Q3 revenue was still 1% lower year over year, while test volume declined 2% year over year. Higher average revenue per test partly offset the volume weakness. Read More.
• Negative Sentiment: Myriad said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential data exposure could create operational, legal, or reputational risks. Read More.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.